124 related articles for article (PubMed ID: 30968859)
1. [Out-patient management of nausea and vomiting in multiday therapy of acute myeloid leukemia in the elderly. Use of granisetron in slow-release transdermal formulation. Clinical case].
Piccioni AL
Recenti Prog Med; 2019 Mar; 110(3):10e-13e. PubMed ID: 30968859
[TBL] [Abstract][Full Text] [Related]
2. [Management of nausea and vomiting in cancer patients. Use of transdermal patches containing granisetron in patients affected by head and neck squamous-cell carcinoma].
Rondonotti D; Gennari A
Recenti Prog Med; 2018 Nov; 109(11):3e-5e. PubMed ID: 30565579
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
[TBL] [Abstract][Full Text] [Related]
4. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
5. Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting.
Spartinou A; Nyktari V; Papaioannou A
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1289-1297. PubMed ID: 29057666
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
7. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients].
Motohashi S; Hori K; Ono T; Ohnishi K; Kawakami J
Yakugaku Zasshi; 2012; 132(5):675-81. PubMed ID: 22687700
[TBL] [Abstract][Full Text] [Related]
9. Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis.
Chua AV; Hernandez ARB; Real IO
Support Care Cancer; 2020 Dec; 28(12):5611-5619. PubMed ID: 32623521
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.
Ono A; Kishimoto K; Hasegawa D; Goldman RD; Kosaka Y
Support Care Cancer; 2019 Mar; 27(3):895-899. PubMed ID: 30066198
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
12. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of granisetron for cancer patients undergoing platinum-based chemotherapy: comparison of 1 miligram versus 3 miligram doses in preventing nausea and vomiting.
Kurnianda J; Hisyam B; Wahyuningsih E; Hutajulu SH
Acta Med Indones; 2005; 37(4):210-3. PubMed ID: 16317218
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
[TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
16. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting.
Schulmeister L
Clin J Oncol Nurs; 2009 Dec; 13(6):711-4. PubMed ID: 19948469
[TBL] [Abstract][Full Text] [Related]
17. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
18. Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Keat CH; Phua G; Abdul Kassim MS; Poh WK; Sriraman M
Asian Pac J Cancer Prev; 2013; 14(1):469-73. PubMed ID: 23534775
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
Goto T; Tanimoto K; Ishibashi M; Okamura S
Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
